Psychopharmacologic Interventions for Repetitive Behaviors in Autism Spectrum Disorders

Child and Adolescent Psychiatric Clinics of North America

Volumn 17, Issue 4, 2008, Pages 753-771

  Soorya, Latha ^a   Kiarashi, Jessica ^a   Hollander, Eric ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; OXYTOCIN; PLACEBO; RISPERIDONE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VALPROATE SEMISODIUM;

AGGRESSION; ANXIETY DISORDER; AREA UNDER THE CURVE; AUTISM; AUTOMUTILATION; BEHAVIOR DISORDER; CLINICAL TRIAL; COMPULSION; DIAPHORESIS; DIARRHEA; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HUMAN; HYPERACTIVITY; INCREASED APPETITE; INSOMNIA; IRRITABILITY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SEDATION; SEIZURE THRESHOLD; SEROTONIN SYNDROME; SIDE EFFECT; STOMACH CRAMP; STOMACH DISEASE; SYMPTOM; TACHYCARDIA; TREATMENT OUTCOME; TREMOR; URINE RETENTION; WEIGHT GAIN;

ADOLESCENT; ADULT; AUTISTIC DISORDER; BRAIN; CHILD; COMPULSIVE BEHAVIOR; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; PSYCHOTROPIC DRUGS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; STEREOTYPIC MOVEMENT DISORDER;

EID: 50449087037     PISSN: 10564993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chc.2008.06.003     Document Type: Review

References (70)

1. Turner M. Annotation: repetitive behaviour in autism: a review of psychological research. J Child Psychol Psychiatry 40 6 (1999) 839-849
2. Baumeister A.A., and Forehand R. Effects of contingent shock and verbal command on body rocking of retardates. J Clin Psychol 28 4 (1972) 586-590
3. Bodfish J.W., Symons F.J., Parker D.E., et al. Varieties of repetitive behavior in autism: comparisons to mental retardation. J Autism Dev Disord 30 3 (2000) 237-243
4. Richler J., Bishop S.L., Kleinke J.R., et al. Restricted and repetitive behaviors in young children with autism spectrum disorders. J Autism Dev Disord 37 1 (2007) 73-85
5. Silverman J.M., Smith C.J., Schmeidler J., et al. Symptom domains in autism and related conditions: evidence for familiality. Am J Med Genet 114 1 (2002) 64-73
6. Lord C., Risi S., DiLavore P.S., et al. Autism from 2 to 9 years of age. Arch Gen Psychiatry 63 6 (2006) 694-701
7. Aman M.G., Lam K.S., and Van Bourgondien M.E. Medication patterns in patients with autism: temporal, regional, and demographic influences. J Child Adolesc Psychopharmacol 15 1 (2005) 116-126
8. DSM-IV, Diagnostic and Statistical Manual of Mental Disorders (Fourth ed.), American Psychiatric Association, Washington, DC (1994).
9. Lord C., and Pickles A. Language level and nonverbal social-communicative behaviors in autistic and language-delayed children. J Am Acad Child Adolesc Psychiatry 35 11 (1996) 1542-1550
10. Szatmari P., Bartolucci G., and Bremner R. Asperger's syndrome and autism: comparison of early history and outcome. Dev Med Child Neurol 31 6 (1989) 709-720
11. McDougle C.J., Kresch L.E., Goodman W.K., et al. A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry 152 5 (1995) 772-777
12. Cuccaro M.L., Shao Y., Grubber J., et al. Factor analysis of restricted and repetitive behaviors in autism using the Autism Diagnostic Interview-R. Child Psychiatry Hum Dev 34 1 (2003) 3-17
13. Bishop S.L., Richler J., and Lord C. Association between restricted and repetitive behaviors and nonverbal IQ in children with autism spectrum disorders. Child Neuropsychol 12 4-5 (2006) 247-267
14. Lam K.S., and Aman M.G. The repetitive behavior scale-revised: independent validation in individuals with autism spectrum disorders. J Autism Dev Disord 37 5 (2007) 855-866
15. Anagnostou E., Chaplin W., Dryden W., et al. Factor analysis of the Y-BOCS in autistic disorder. Neuropsychopharmacology 30 1 (2005) S153
16. Hutt C., Hutt S.J., and Ounsted C. The behaviour of children with and without upper CNS lesions. Behaviour 24 3 (1965) 246-268
17. Cook E.H., and Leventhal B.L. The serotonin system in autism. Curr Opin Pediatr 8 4 (1996) 348-354
18. McFarlane H.G., Kusek G.K., Yang M., et al. Autism-like behavioral phenotypes in BTBR T+tf/J mice. Genes Brain Behav 7 2 (2008) 152-163
19. Schain R.J., and Freedman D.X. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr 58 (1961) 315-320
20. Owley T. The pharmacological treatment of autistic spectrum disorders. CNS Spectr 7 9 (2002) 663-669
21. McDougle C.J., Naylor S.T., Cohen D.J., et al. Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry 53 11 (1996) 993-1000
22. Novotny S., Hollander E., Allen A., et al. Increased growth hormone response to sumatriptan challenge in adult autistic disorders. Psychiatry Res 94 2 (2000) 173-177
23. Chugani D.C., Muzik O., Behen M., et al. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol 45 3 (1999) 287-295
24. Kaplan A., and Hollander E. A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr Serv 54 8 (2003) 1111-1118
25. Moore M.L., Eichner S.F., and Jones J.R. Treating functional impairment of autism with selective serotonin reuptake inhibitors. Ann Pharmacother 38 9 (2004) 1515-1519
26. Stahl S.M. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 51 3 (1998) 215-235
27. Posey D.J., Erikson C.A., Stigler K.A., et al. The use of selective serotonin reuptake inhibitors in autism and related disorders. J Child Adolesc Psychopharmacol 16 1-2 (2006) 181-186
28. Kolevzon A., Mathewson K.A., and Hollander E. Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability. J Clin Psychiatry 67 3 (2006) 407-414
29. Hollander, E, Anagnostou, E, editors. Clinical manual for the treatment of autism. Treatment of autism with selective serotonin reuptake inhibitors and other antidepressants. Washington, D.C.: American Psychiatric Publishing; 2007; 81-97.
30. Flament M.F., Rapaport J.L., Berg C.J., et al. Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. Arch Gen Psychiatry 42 10 (1985) 977-983
31. Leonard H.L., Swedo S.E., Rapaport J.L., et al. Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparison. Arch Gen Psychiatry 46 12 (1989) 1088-1092
32. Gordon C.T., State R.C., Nelson J.E., et al. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 50 6 (1993) 441-447
33. Brasic J.R., Barnett J.Y., Sheitman B.B., et al. Adverse effects of clomipramine. J Am Acad Child Adolesc Psychiatry 36 9 (1997) 1165-1166
34. Sanchez L.E., Campbell M., Small A.M., et al. A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry 35 4 (1996) 537-544
35. Remington G., Sloman L., Konstantareas M., et al. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 21 4 (2001) 440-444
36. Narita N., Hashimoto K., Tomitaka S., et al. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 307 1 (1996) 117-119
37. McDougle C.J., Naylor S.T., Cohen D.J., et al. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53 11 (1996) 1001-1008
38. McDougle C.J., Kresch L.E., and Posey D.J. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord 30 5 (2000) 427-435
39. Fluvoxamine [package insert]. Switzerland: Solvay Pharmaceuticals; 1984.
40. Hollander E., Phillips, A., Chaplin W., et al. A placebo-controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 30 3 (2005) 582-589
41. Buchsbaum M.S., Hollander E., Haznedar M.M., et al. Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. Int J Neuropsychopharmacol 4 2 (2001) 119-125
42. Fatemi S.H., Realmuto J.M., Khan L., et al. Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord 28 4 (1998) 303-307
43. Markowitz P.I. Effect of fluoxetine on self-injurious behavior in the developmentally disabled: a preliminary study. J Clin Psychopharmacol 12 1 (1992) 27-31
44. DeLong G.R., Ritch C.R., and Burch S. Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol 44 10 (2002) 652-659
45. Scahill L., Riddle M.A., McSwiggen-Hardin M., et al. Children-s Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 36 6 (1997) 844-852
46. McDougle C.J., Brodkin E.S., Naylor S.T., et al. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol 18 1 (1998) 62-66
47. Steingard R.J., Zimnitzky B., DeMaso D.R., et al. Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol 7 1 (1997) 9-15
48. Willetts J., Lippa A., and Beer B. Clinical development of citalopram. J Clin Psychopharmacol 19 5 Suppl 1 (1999) 36S-46S
49. Namerow L.B., Thomas P., Bostic J.Q., et al. Use of citalopram in pervasive developmental disorders. J Dev Behav Pediatr 24 2 (2003) 104-108
50. Owley T., Walton L., Salt J., et al. An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 44 4 (2005) 343-348
51. Carrasco J.L., and Sandner C. Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. Int J Clin Pract 59 12 (2005) 1428-1434
52. Sikich L., Hickok J.M., and Todd R.D. 5-HT1A receptors control neurite branching during development. Brain Res Dev Brain Res 56 2 (1990) 269-274
53. Mooney R.D., Shi M.Y., and Rhoades R.W. Modulation of retinotectal transmission by presynaptic 5-HT1B receptors in the superior colliculus of the adult hamster. J Neurophysiol 72 1 (1994) 3-13
54. Salichon N., Gaspar P., Upton A.L., et al. Excessive activation of serotonin (5-HT) 1B receptors disrupts the formation of sensory maps in monoamine oxidase a and 5-ht transporter knock-out mice. J Neurosci 21 3 (2001) 884-896
55. Mazer C., Muneyyirci J., Taheny K., et al. Serotonin depletion during synaptogenesis leads to decreased synaptic density and learning deficits in the adult rat: a possible model of neurodevelopmental disorders with cognitive deficits. Brain Res 760 1-2 (1997) 68-73
56. Osterheld-Haas M.C., and Hornung J.P. Laminar development of the mouse barrel cortex: effects of neurotoxins against monoamines. Exp Brain Res 110 2 (1996) 183-195
57. Yan W., Wilson C.C., and Haring J.H. 5-HT1a receptors mediate the neurotrophic effect of serotonin on developing dentate granule cells. Brain Res Dev Brain Res 98 2 (1997) 185-190
58. McDougle C.J., Homes J.P., Carlson D.C., et al. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 55 7 (1998) 633-641
59. McDougle C.J., Fleishmann R.L., Epperson C.N., et al. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry 56 11 (1995) 526-528
60. Witwer A., and Lecavalier L. Treatment incidence and patterns in children and adolescents with autism spectrum disorders. J Child Adolesc Psychopharmacol 15 4 (2005) 671-681
61. McDougle C.J., Epperson C.N., Pelton G.H., et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 57 8 (2000) 794-801
62. McDougle C.J., Scahil L., Aman M.G., et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 162 6 (2005) 1142-1148
63. Hollander E., Tracey K.A., Swann A.C., et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 28 6 (2003) 1186-1197
64. Hollander E. Managing aggressive behavior in patients with obsessive-compulsive disorder and borderline personality disorder. J Clin Psychiatry 60 Suppl 15 (1999) 38-44
65. Insel T.R., O'Brien D.J., and Leckman J.F. Oxytocin, vasopressin, and autism: is there a connection?. Biol Psychiatry 45 2 (1999) 145-157
66. Kosfeld M., Heinrichs M., Zak P.J., et al. Oxytocin increases trust in humans. Nature 435 7042 (2005) 673-676
67. Domes G., et al. Oxytocin improves mind-reading in humans. Biol Psychiatry 61 6 (2007) 731-733
68. Hollander E., Novotny S., Hanratty M., et al. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology 28 1 (2003) 193-198
69. Hollander E., Soorya S., Wasseman S., et al. Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol 9 2 (2006) 209-213
70. Hollander E, Soorya L, Chaplin W, et al. Placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autistic disorder. In preparation.